News in Brief

UK site acquisition strengthens KD Pharma’s omega-3 capacity

By Nathan Gray contact

- Last updated on GMT

UK site acquisition strengthens KD Pharma’s omega-3 capacity
Global omega-3 player KD Pharma says the new site at Seal Sands will expand its capacity for manufacturing omega-3-based intermediates, especially for those use in producing active pharmaceutical ingredients (APIs).

The facility, close to Middlesbrough, UK, was previously used for manufacturing omega-3 products.

“This acquisition expands our technology and manufacturing base for producing APIs with the highest concentrations of EPA and DHA omega-3s,”​ commented Oscar Groet, CEO of KD Pharma Group.

KD Pharma said it strives to be the leading manufacturer in the rapidly growing omega-3 API market.

“The breadth of our technology platform sets KD Pharma apart, no company has more technologies for isolating and fractionating lipids,”​ added Groet.

The UK site acquisition will enable it to meet market demand for the highest quality APIs in response to new product approvals, label expansions, and supportive clinical research, said the firm.

The company says the site will be brought online this year and operated alongside its other manufacturing sites in Bexbach, Germany; Brattvag, Norway; and Miami, United States.

Related products

show more

Clinically Proven Omega-3 formula for Joint Health

Clinically Proven Omega-3 formula for Joint Health

KD Pharma Group | 29-Apr-2019 | Data Sheet

KD Nutra is pleased to announce the completion of a clinical trial for its Move3™ omega-3 joint formulation. The trial has shown that Move3™ has a significant...

Omegavie® DHA algae Capsules

Omegavie® DHA algae Capsules

POLARIS | 23-Aug-2018 | Application Note

Omegavie® DHA algae capsules is a real opportunity to consume high-performing Omega-3 DHA 100% vegan, natural, sustainable, GMO- and allergen-free. Designed...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars